Group 1: Kraig Biocraft Laboratories - Kraig Biocraft Laboratories' recombinant spider silk technology has gained significant visibility by being featured on the cover of National Geographic's March 2026 issue, which could lead to increased investor interest [2][4] - The company is set to deploy approximately one million proprietary silkworm eggs across three facilities in Vietnam, aiming for a production target of up to 10 metric tons of cocoons per month starting in March 2026 [5] - Scientific validation published in the Proceedings of the National Academy of Sciences confirms that Kraig's fibers are tougher than conventional silk and comparable to native spider dragline silk [5] - If successful, Kraig could become the second company to achieve sustained commercial production from a transgenic animal platform, a milestone previously associated with ATryn [6] - Investors are closely monitoring for initial deliveries to global brand partners in luxury fashion and performance sportswear, which could transition Kraig from a research-focused entity to a specialty materials platform [8] Group 2: Gilead Sciences and Arcellx - Gilead Sciences has announced a definitive agreement to acquire Arcellx for $115 per share in cash, plus a $5 contingent value right, representing an implied equity value of approximately $7.8 billion [9] - The acquisition provides Gilead with full control of anitocabtagene autoleucel, a CAR T-cell therapy for multiple myeloma, with the FDA accepting the BLA and a PDUFA action date set for December 23, 2026 [10] - Gilead's CEO emphasized the potential of anito-cel to become a foundational treatment for multiple myeloma and its importance in enhancing Gilead's oncology and inflammation capabilities [11] Group 3: ImmunityBio - ImmunityBio reported approximately $113 million in net product revenue for ANKTIVA in 2025, reflecting a 700% year-over-year growth [13] - The company also experienced a 750% increase in unit sales volume and expanded regulatory authorization across 33 countries [13] - ImmunityBio is positioning ANKTIVA as a backbone immunotherapy platform with ongoing randomized trials and long-term patent protection extending beyond 2035 [15] Group 4: Getty Images and Shutterstock - Getty Images and Shutterstock received unconditional antitrust clearance from the U.S. Department of Justice for their proposed merger, which aims to strengthen their financial foundation and competitive positioning in the visual content market [16][17]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misrepresenting information regarding its drug AMT-130 during a specific class period, leading to significant stock price decline [1]. Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, focusing on gene therapies for severe diseases, including Huntington's disease [1]. Legal Allegations - The lawsuit claims that uniQure misrepresented the FDA approval status of its Pivotal Study for AMT-130 and downplayed the potential delay in its Biologics License Application (BLA) timeline [1]. - The complaint highlights that the FDA did not agree that the Phase I/II data could serve as primary evidence for a BLA submission, causing uncertainty regarding the submission timeline [1]. Stock Performance Impact - Following the disclosure on November 3, 2025, uniQure's stock plummeted over 49%, dropping from $67.69 per share on October 31, 2025, to $34.29 per share the next trading day [1].

Company Overview - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - INmune Bio Inc. is advancing its clinical development of XPro1595 for early Alzheimer's disease, with a webinar scheduled to discuss the registrational pathway and recent trial results [1][2]. Group 1: Clinical Development - The Phase 2 MINDFuL trial has been completed, and feedback from the FDA supports moving to a registrational study for Alzheimer's patients with inflammation biomarkers [2]. - XPro1595 is a next-generation selective soluble TNF inhibitor aimed at restoring immune homeostasis in the brain without affecting transmembrane TNF or TNF receptors [3][10]. Group 2: Webinar Details - The webinar will cover three main topics: results from the MINDFuL trial, the design of the registrational study, and the strategic roadmap to Phase 3, including global partnership opportunities [3][4][5]. - Featured speakers include Dr. Michael Woodward and Dr. Sharon Cohen, both recognized experts in Alzheimer's disease research [6]. Group 3: Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system, with three product platforms: CORDStrom™, XPro™, and INKmune® [11].

Financial Performance - Moderna's revenue surged from approximately $60 million in 2020 to over $19 billion in 2023 due to its mRNA technology and COVID-19 vaccine development [1][3] - However, COVID-related revenue has declined to $1.9 billion, and the company's cash reserves have decreased from over $10 billion to roughly $5.8 billion [4] Product Development - Moderna is currently developing an influenza vaccine that is under review by the FDA, with potential approval before the next flu season [5] - The company is collaborating with Merck on a melanoma therapy, which shows promising trial results but is still in the testing phase [6] Future Outlook - There is caution regarding Moderna's future as it has not yet launched a major new product following its COVID success, leading to elevated spending and stagnant revenue growth [7]

Core Insights - Anixa Biosciences, Inc. is focused on cancer treatment and prevention, with a key highlight being Dr. Jose Conejo-Garcia's keynote speech at the SCTR 2026 Retreat, discussing the company's CAR-T technology and ongoing clinical trials [1][2]. Group 1: Company Overview - Anixa is a clinical-stage biotechnology company dedicated to cancer treatment and prevention, with a therapeutic portfolio that includes liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy developed in collaboration with Moffitt Cancer Center [5]. - The company utilizes a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by using the natural ligand of the FSHR receptor instead of an antibody fragment [5]. - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers, focusing on immunizing against specific proteins expressed in certain cancer forms [5]. Group 2: Clinical Trials and Research - The ongoing Phase 1 clinical trial of lira-cel targets adult women with recurrent ovarian cancer who have progressed after at least two prior therapies, utilizing the FSHR-mediated CAR-T therapy [4]. - Dr. Conejo-Garcia's presentation at the SCTR 2026 Retreat will cover the advancements and findings from the ongoing clinical trial of lira-cel [2]. Group 3: Industry Collaboration - The SCTR 2026 Retreat aims to foster collaboration among pioneers in research, clinical care, and industry, showcasing innovations in advanced cell therapy, immune therapy, and oncology [3].

Core Viewpoint - FibroBiologics, Inc. has received an extension from a Nasdaq Hearings Panel to regain compliance for continued listing on The Nasdaq Capital Market, providing a clear path for the company to maintain its stock listing [1][2]. Group 1: Compliance Conditions - The company must meet an equity standard of $2.5 million under Nasdaq Listing Rule 5550(b)(1) by February 27, 2026, as an alternative to the $35 million minimum Market Value of Listed Securities under Listing Rule 5550(b)(2) [2]. - FibroBiologics is required to meet the minimum bid price requirement of $1.00 per share by April 13, 2026, as per Nasdaq Listing Rule 5550(a)(2) [2]. - The company must comply with all applicable criteria for continued listing on Nasdaq by April 13, 2026 [2]. Group 2: Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, focusing on developing therapeutics and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials [4]. - The company holds over 270 patents issued and pending in the US and internationally, covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [4]. - FibroBiologics represents a new generation of medical advancements in cell therapy and tissue regeneration [4].

Core Insights - Proactive provides fast, accessible, and actionable business and finance news content to a global investment audience [2] - The company specializes in medium and small-cap markets while also covering blue-chip companies and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, mining, oil and gas, and emerging technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - TG Therapeutics, Inc. will hold a conference call on February 26, 2026, to discuss its financial results for Q4 and full year 2025, along with a business outlook for 2026 [1]. Group 1: Conference Call Details - The conference call will take place at 8:30 AM ET and will be hosted by Michael S. Weiss, Chairman and CEO [1]. - Participants can join the call by dialing 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside the U.S.) [2]. - A live webcast will be available on the company's website, and an audio recording will be accessible for 30 days post-call [2][3]. Group 2: Company Overview - TG Therapeutics is a biotechnology company focused on developing and commercializing treatments for B-cell diseases [4]. - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis [4]. - BRIUMVI has also been approved by several regulatory agencies outside the U.S. for treating adult patients with active relapsing multiple sclerosis [4].

Core Viewpoint - PCI Biotech Holding ASA is proposing to dissolve the company and delist its shares from Euronext Oslo Børs due to the absence of operational activity and the expectation that such activity will not resume [2][3]. Group 1: Company Dissolution - The Board of Directors has proposed the resolution to dissolve PCI Biotech as there is no longer any operational activity within the company [2]. - The wholly owned subsidiary, PCI Biotech AS, has also resolved to initiate a parallel dissolution process [2]. Group 2: Delisting from Euronext Oslo Børs - The proposed resolution to delist the shares is based on the lack of operational activity and a limited asset base, leading the Board to conclude that the company is no longer suitable for public trading [3]. - The Board recommends that the delisting should occur as soon as possible [3].